Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
FT836 · 1 trial · 6 indications
The number of participants experiencing ≥1 DLT will be reported.
The severity of DLTs will be determined according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE, v5.0).
| Arm | Type | Description |
|---|---|---|
| Regimen A ( FT836) | EXPERIMENTAL | Participants receive FT836 monotherapy |
| Regimen B ( Paclitaxel + FT836) | EXPERIMENTAL | Participants receive Paclitaxel chemotherapy followed by FT836 |
| Regimen C ( Cetuximab + FT836) | EXPERIMENTAL | Participants receive FT836 combined with cetuximab |
| Regimen D ( Paclitaxel + Cetuximab + FT836) | EXPERIMENTAL | Participants receive Paclitaxel chemotherapy followed by FT836 combined with cetuximab |
| Regimen E ( Trastuzumab + FT836)) | EXPERIMENTAL | Participants receive FT836 combined with trastuzumab |
| Regimen F ( Paclitaxel + Trastuzumab + FT836) | EXPERIMENTAL | Participants receive Paclitaxel chemotherapy followed by FT836 combined with trastuzumab |
| Name | Type | Description |
|---|---|---|
| FT836 | DRUG | FT836 drug product is administered as an intravenous infusion on multiple days schedule at treatment cycle. |
| Paclitaxel | DRUG | IV infusion ; 80 mg/m2 QW; Days -21, -14, and -7 |
| Cetuximab | DRUG | Cetuximab administration will begin on Day -4 at the recommended initial dose of 400 mg/m2 as a 120-minute IV infusion |
| Trastuzumab | DRUG | trastuzumab administration will begin on Day -4 at an initial dose of 4 mg/kg as a 90-minute IV infusion. |
Inclusion Criteria: * For all regimens, disease that is not amenable to curative therapy and that has relapsed or progressed following at least one line of prior systemic therapy. * Evidence of adequate organ function as determined by all of the following: * Absolute neutrophil count (ANC) \>100...
Top 20 of 84 competitors
FT836 is an investigational small molecule being studied for the treatment of advanced solid tumors, including non-small cell lung cancer, colorectal cancer, breast cancer, ovarian cancer, endometrial carcinoma, and head and neck squamous cell carcinoma. It is currently in Phase 1 clinical development.
FT836 is being developed by Fate Therapeutics, Inc., a biopharmaceutical company traded on NASDAQ under the ticker symbol FATE. The company is conducting a Phase 1 clinical trial to evaluate the drug in participants with advanced solid tumors.
FT836 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The ongoing Phase 1 trial is actively recruiting participants in the United States.
FT836 is being evaluated in a Phase 1 clinical trial with the identifier NCT07216105. The trial is studying FT836 with or without chemotherapy and/or monoclonal antibodies in participants with advanced solid tumors, including non-small cell lung cancer. The trial is currently recruiting and aims to enroll 113 participants.
Yes, FT836 is being studied in non-small cell lung cancer as part of a Phase 1 clinical trial. The trial also includes participants with colorectal cancer, breast cancer, ovarian cancer, endometrial carcinoma, and head and neck squamous cell carcinoma. The study is enrolling adults aged 18 years and older.